Walder Wyss advises BC Platforms on $15 million Series C Financing and on a Partnership with IQVIA to Extend Data Analytics in Genomics
18 December 2019 – BC Platforms announced that it has closed a USD 15 million financing round alongside a new commercial collaboration with IQVIA™ (NYSE: IQV). The round was led by IQVIA in conjunction with Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company. As part of the collaboration, IQVIA and BC Platforms plan to launch new data driven technologies, integrating complex clinical and genomic data.
BC Platforms is a world leader in genomic data management and analytics. Through the commercial collaboration between IQVIA and BC Platforms, the partners plan to build a world leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine. BC Platforms will use the fundraising proceeds to expand its global network of clinical and genomics data. BC Platforms is headquartered in Zurich, Switzerland.
Walder Wyss acted as advisor to BC Platforms in this transaction. The team was being led by Alexander Gutmans (Partner, Corporate/M&A), Markus Vischer (Partner, Corporate/M&A) and included Markus Schülin (Counsel, Notary Public), Rafael Zemp (Managing Associate, Corporate/M&A), Nico Bernhard (Associate, Corporate/M&A) and Karina Tschon (Associate, Corporate/M&A).